Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00619684 · OUTCOME

Number of Patients Requiring Dose Interruption, Dose Reduction or Discontinuance of Lenalidomide

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant · Source last updated 2017-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 9 years

What was measured

Dose interruption, dose reduction or discontinuation of lenalidomide due to toxicity, GVHD or disease progression

Analysis population: Patients enrolled on the trial who received lenalidomide treatment.

Groups in this outcome

Treatment (Lenalidomide)

Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide)18

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)13Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        13
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Dose interruption, dose reduction or discontinuation of lenalidomide due to toxicity, GVHD or disease progression
groups
  1. description
    Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO
    id
    OG000
    title
    Treatment (Lenalidomide)
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients enrolled on the trial who received lenalidomide treatment.
reporting Status
POSTED
time Frame
Up to 9 years
title
Number of Patients Requiring Dose Interruption, Dose Reduction or Discontinuance of Lenalidomide
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice